Floatz logo

Mevrometostat

Prostate Cancer (Adenocarcinoma)

Prostate Cancer Clinical Trials ConsortiumSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

96 Active assets in the Prostate Cancer (Adenocarcinoma) cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB

View all 50 →

Same molecule, other indications

Mevrometostat is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →